Companies: 10,795·Total market cap: $144.5T
KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc.

KALVNASDAQHealthcare● Active
$26.98
+$0.03(+0.09%)
Market Cap$1.4B
P/E Ratio
52W High$26.98
52W Low$9.83

KalVista Pharmaceuticals, Inc. (KALV) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

KALV · net income · updated Jun 8, 2026

Core profitability metrics

Net income was −$164.3M for FY2025 (fiscal year ending 2025-12-31), up 10.4% year-over-year. Net profit margin was -223.2%.

FY2025 Net Income−$164.3M▲ +10.4% YoY
Trailing 12M (TTM)−$138.4Mtrailing 4 quarters sum
Net Profit Margin-223.2%−$164.3M ÷ $73.6M
YoY Change+10.4%
5-Year CAGRN/AN/A — contains loss years
FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0
Source: FMP /income-statement · US GAAP · USDUpdated: Jun 8, 2026

Annual net income history

Net IncomeNet LossNet Margin %

▸ FMP /income-statement · Annual · KALV net income history · KALV profit margin

Annual net income data

Fiscal YearNet IncomeYoY ChangeNet Margin
FY2025Loss−$164.3M▲ +10.4%-223.2%
FY2025Loss−$183.4M▼ 44.9%
FY2024Loss−$126.6M▼ 36.3%
FY2023Loss−$92.9M▼ 12.8%
FY2022Loss−$82.3M▼ 78.1%

Net income vs peers (Healthcare)

#CompanyNet IncomeYoY
#1
KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc.YOU
KALV
−$164.3M+10.4%
#2
Johnson & Johnson
Johnson & Johnson
JNJ
$26.80B+90.6%
#3
Eli Lilly and Company
Eli Lilly and Company
LLY
$20.64B+94.9%
#4
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$12.06B-16.3%
#5
AbbVie Inc.
AbbVie Inc.
ABBV
$4.23B-1.2%
Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

KalVista Pharmaceuticals, Inc. (KALV) reported net income of −$164.3M for FY2025 (fiscal year ending 2025-12-31), up 10.4% year-over-year. The net profit margin was -223.2% — meaning the company kept $-2.23 of every dollar of revenue as profit.

KalVista Pharmaceuticals, Inc. has not yet achieved annual profitability based on available data (14 fiscal years). The company has reported net losses across all available periods.

KalVista Pharmaceuticals, Inc.'s net profit margin was -223.2% for FY2025, based on the latest annual results.

Investors sometimes search for "KalVista Pharmaceuticals, Inc. net worth" — the company's market capitalization is a separate figure from KALV net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Frequently asked questions

KALV net income · 4 questions

KalVista Pharmaceuticals, Inc. is not currently profitable on an annual basis. The company reported a net loss of $164.3M for FY2025.

is KALV profitabledoes KALV make a profitKALV profitabilityKALV profitable company

Source: FMP /income-statement · GAAP · KalVista Pharmaceuticals, Inc. · KalVista Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026